Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + pertuzumab + palbociclib + exemestane
- Development stage
- Unknown
- Lead developer
- Anhui Provincial Tumor Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of two HER2-targeted monoclonal antibodies (trastuzumab and pertuzumab), a CDK4/6 inhibitor (palbociclib), and a steroidal aromatase inhibitor (exemestane). It is being investigated as a chemotherapy-free neoadjuvant treatment for patients with triple-positive breast cancer (HER2-positive and hormone receptor-positive). Trastuzumab and pertuzumab work synergistically to inhibit HER2 signaling by binding to different extracellular domains of the receptor. Palbociclib arrests the cell cycle at the G1 phase by inhibiting CDK4 and CDK6, while exemestane reduces estrogen levels by irreversibly binding to the aromatase enzyme. The study is led by Anhui Provincial Cancer Hospital and utilizes biosimilars QL1701 (trastuzumab) and QL1209 (pertuzumab) developed by Qilu Pharmaceutical.
- Other names
- trastuzumab + pertuzumab + palbociclib + exemestane-Anhui Provincial Cancer Hospital-breast cancer
02
Targets
CYP19A1 (Aromatase)CDK6 (Cyclin-dependent kinase 6)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on trastuzumab + pertuzumab + palbociclib + exemestane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + pertuzumab + palbociclib + exemestane.